High lifetime risk of cancer in primary sclerosing cholangitis
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J. A., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,959
Christakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
WINAWER, S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50044 · Cited by 2,143
Riddell, R. H., Goldman, H., Ransohoff, D. F., Appelman, H. D., Fenoglio, C. M., Haggitt, R. C., hren, C., Correa, P., Hamilton, S. R., Morson, B. C., et al. (1983) · Human Pathology · doi:10.1016/s0046-8177(83)80175-0 · Cited by 1,862
Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.
Broomé, U., Olsson, R., Lööf, L., Bodemar, G., Hultcrantz, R., Danielsson, A., Prytz, H., Sandberg-Gertzén, H., Wallerstedt, S., & Lindberg, G. (1996) · Gut · doi:10.1136/gut.38.4.610 · Cited by 819
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
Chapman, R. W., Arborgh, B. A., Rhodes, J. M., Summerfield, J. A., Dick, R., Scheuer, P. J., & Sherlock, S. (1980) · Gut · doi:10.1136/gut.21.10.870 · Cited by 732
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Hepatic and extrahepatic malignancies in primary sclerosing cholangitis
Bergquist, A., Ekbom, A., Olsson, R., Kornfeldt, D., Lööf, L., Danielsson, Å., Hultcrantz, R., Lindgren, S., Prytz, H., Sandberg-Gertzén, H., et al. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00288-4 · Cited by 717 · cited 1×
“The reported overall risk for CCA varies from 8% to 36% [3–6] and the 10-year cumulative incidence from 11% to 31% [3,7–9].”
BackgroundPrimary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
Broomé, U., Löfberg, R., Veress, B., & Eriksson, L. S. (1995) · Hepatology · doi:10.1002/hep.1840220511 · Cited by 481
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Risk factors for cholangiocarcinoma
Tyson, G. L., & El-Serag, H. B. (2011) · Hepatology · doi:10.1002/hep.24351 · Cited by 956
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update
Khan, S. A., Davidson, B. R., Goldin, R. D., Heaton, N., Karani, J., Pereira, S. P., Rosenberg, W. M. C., Tait, P., Taylor-Robinson, S. D., Thillainayagam, A. V., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301748 · Cited by 797
Boonstra, K., Weersma, R. K., van Erpecum, K. J., Rauws, E. A., Spanier, B. W. M., Poen, A. C., van Nieuwkerk, K. M., Drenth, J. P., Witteman, B. J., Tuynman, H. A., et al. (2013) · Hepatology · doi:10.1002/hep.26565 · Cited by 725
“The vast majority of investigators use time of diagnosis as the starting point for follow-up.(1,2,5,8,9) Definition of PSC-related death differs between studies.”
BackgroundMethodInfluentialSelf-citationEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
Interaction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 581
Weismüller, T. J., Trivedi, P. J., Bergquist, A., Imam, M., Lenzen, H., Ponsioen, C. Y., Holm, K., Gotthardt, D., Färkkilä, M. A., Marschall, H.-U., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.038 · Cited by 533
Van Assche, G., Dignass, A., Bokemeyer, B., Danese, S., Gionchetti, P., Moser, G., Beaugerie, L., Gomollón, F., Häuser, W., Herrlinger, K., et al. (2013) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.005 · Cited by 463
Primary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 344
Cancer surveillance in patients with primary sclerosing cholangitis
Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 292
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009
Aljiffry, M., Walsh, M. J., & Molinari, M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4240 · Cited by 286
Chapman, M. H., Thorburn, D., Hirschfield, G. M., Webster, G. G. J., Rushbrook, S. M., Alexander, G., Collier, J., Dyson, J. K., Jones, D. E., Patanwala, I., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317993 · Cited by 284
Pedersen, N., Duricova, D., Elkjaer, M., Gamborg, M., Munkholm, P., & Jess, T. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.760 · Cited by 277
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease
Boonstra, K., van Erpecum, K. J., van Nieuwkerk, K. M. J., Drenth, J. P. H., Poen, A. C., Witteman, B. J. M., Tuynman, H. A. R. E., Beuers, U., & Ponsioen, C. Y. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22938 · Cited by 262
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis
Vries, A. B. D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1956 · Cited by 253
Autoimmune liver disease, autoimmunity and liver transplantation
Carbone, M., & Neuberger, J. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.020 · Cited by 250
Deneau, M. R., El‐Matary, W., Valentino, P. L., Abdou, R., Alqoaer, K., Amin, M., Amir, A. Z., Auth, M., Bazerbachi, F., Broderick, A., et al. (2017) · Hepatology · doi:10.1002/hep.29204 · Cited by 230
Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J. J., & Parsi, M. A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.09.015 · Cited by 203
Trivedi, P. J., Crothers, H., Mytton, J., Bosch, S., Iqbal, T., Ferguson, J., & Hirschfield, G. M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.049 · Cited by 183
Zheng, H.-H., & Jiang, X.-L. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000576 · Cited by 159
Jrgensen, K. K., Grzyb, K., Lundin, K. E. A., Clausen, O. P. F., Aamodt, G., Schrumpf, E., Vatn, M. H., & Boberg, K. M. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21699 · Cited by 149
Sinakos, E., Saenger, A. K., Keach, J., Kim, W. R., & Lindor, K. D. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.02.007 · Cited by 142
Primary sclerosing cholangitis: diagnosis, prognosis, and management
Singh, S., & Talwalkar, J. A. (2013) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.02.016 · Cited by 119
de Valle, M. B., Björnsson, E., & Lindkvist, B. (2012) · Liver International · doi:10.1111/j.1478-3231.2011.02614.x · Cited by 114
Shah, S. C., ten Hove, J. R., Castaneda, D., Palmela, C., Mooiweer, E., Colombel, J.-F., Harpaz, N., Ullman, T. A., van Bodegraven, A. A., Jansen, J. M., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.023 · Cited by 109
Ponsioen, C. Y., Assis, D. N., Boberg, K. M., Bowlus, C. L., Deneau, M., Thorburn, D., Aabakken, L., Färkkilä, M., Petersen, B., Rupp, C., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.046 · Cited by 95
Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis
Zenouzi, R., Weismüller, T. J., Hübener, P., Schulze, K., Bubenheim, M., Pannicke, N., Weiler–Normann, C., Lenzen, H., Manns, M. P., Lohse, A. W., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.008 · Cited by 86
Barner-Rasmussen, N., Pukkala, E., Jussila, A., & Färkkilä, M. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2019.1707277 · Cited by 80
“6% of the PSC patients in the HUS cohort were diagnosed with CCA, which is lower than previously published, 7–9% [14,16].”
BackgroundTrivedi, P. J., Corpechot, C., Pares, A., & Hirschfield, G. M. (2016) · Hepatology · doi:10.1002/hep.28128 · Cited by 71
“Relapsing-remitting episodes of acute cholangitis are a frequent concern; and data from several cohorts suggest symptomatic presentations carry poorer TFS and malignancy-free survival.(18,20) One third of CCA are diagnosed within the first year of PSC presentation (annual incidence thereafter: 0.”
BackgroundJørgensen, K. K., Lindström, L., Cvancarova, M., Castedal, M., Friman, S., Schrumpf, E., Foss, A., Isoniemi, H., Nordin, A., Holte, K., et al. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.685754 · Cited by 65
“In consistency with earlier studies of PSC patients with IBD, the risk of colorectal neoplasia increased with time [6,7,9,10].”
ResultVenkatesh, P. G. K., Navaneethan, U., Shen, B., & McCullough, A. J. (2013) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2401-3 · Cited by 49
Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis
Levy, C., & Martin, E. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608655 · Cited by 46
Wannhoff, A., Rupp, C., Friedrich, K., Brune, M., Knierim, J., Flechtenmacher, C., Sauer, P., Stremmel, W., Hov, J. R., Schirmacher, P., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.014 · Cited by 34
Estimating a population cumulative incidence under calendar time trends
Hansen, S. N., Overgaard, M., Andersen, P. K., & Parner, E. T. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-016-0280-6 · Cited by 24
Wannhoff, A., Brune, M., Knierim, J., Weiss, K. H., Rupp, C., & Gotthardt, D. N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15146 · Cited by 17
“This disease is characterised by a high rate of malignancy development.1–3 In fact, malignancies are the number one cause of death in patients with PSC.4,5 The risk for biliary tract cancer (BTC), mostly cholangiocarci- noma and to a lesser extent gall bladder carcinoma, is dramatically increased in these patients.6–8…”
BackgroundInfluential
Metadata
- Authors
- Claessen, M. M. H., Vleggaar, F. P., Tytgat, K. M. A. J., Siersema, P. D., & van Buuren, H. R.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2009-01
- Volume
- 50
- Issue
- 1
- Pages
- 158-164
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2097879197
- Cited by
- 412
- References
- 38
- FWCI
- 11.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.